-
1
-
-
0037364074
-
Tamoxifen: a most unlikely pioneering medicine
-
Jordan, V. C. Tamoxifen: a most unlikely pioneering medicine Nat. Rev. Drug Discovery 2003, 2, 205-213 10.1038/nrd1031
-
(2003)
Nat. Rev. Drug Discovery
, vol.2
, pp. 205-213
-
-
Jordan, V.C.1
-
2
-
-
85012009358
-
Estrogen receptors as therapeutic targets in breast cancer
-
Eckhard, O. Weinmann, H. Wiley-VCH Verlag GmbH: Weinheim, Germany
-
Ariazi, E. A.; Jordan, V. C. Estrogen receptors as therapeutic targets in breast cancer. In Nuclear Receptors as Drug Targets; Eckhard, O.; Weinmann, H.; Eds.; Wiley-VCH Verlag GmbH: Weinheim, Germany, 2008; pp 127-199.
-
(2008)
Nuclear Receptors as Drug Targets
, pp. 127-199
-
-
Ariazi, E.A.1
Jordan, V.C.2
-
3
-
-
0036998677
-
Fulvestrant ("Faslodex") - a new treatment option for patients progressing on prior endocrine therapy
-
Morris, C.; Wakeling, A. E. Fulvestrant ("Faslodex")-a new treatment option for patients progressing on prior endocrine therapy Endocr.-Relat. Cancer 2002, 9, 267-276 10.1677/erc.0.0090267
-
(2002)
Endocr.-Relat. Cancer
, vol.9
, pp. 267-276
-
-
Morris, C.1
Wakeling, A.E.2
-
4
-
-
33646930743
-
Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-α
-
Nephew, K. P.; Long, X. Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-α J. Biol. Chem. 2006, 14, 9607-9615 10.1074/jbc.M510809200
-
(2006)
J. Biol. Chem.
, vol.14
, pp. 9607-9615
-
-
Nephew, K.P.1
Long, X.2
-
6
-
-
80051956348
-
Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer
-
Scott, S. M.; Brown, M.; Come, S. E. Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer Expert Opin. Drug Saf. 2011, 10, 819-826 10.1517/14740338.2011.595560
-
(2011)
Expert Opin. Drug Saf.
, vol.10
, pp. 819-826
-
-
Scott, S.M.1
Brown, M.2
Come, S.E.3
-
7
-
-
84931395503
-
Endocrine resistance: mechanisms and therapeutic targets
-
Damodaran, S.; Majumder, S.; Ramaswamy, B. Endocrine resistance: mechanisms and therapeutic targets Clin. Invest. 2013, 3, 681-690 10.4155/cli.13.49
-
(2013)
Clin. Invest.
, vol.3
, pp. 681-690
-
-
Damodaran, S.1
Majumder, S.2
Ramaswamy, B.3
-
8
-
-
84884559238
-
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts
-
Li, S.; Shen, D.; Shao, J.; Crowder, R.; Liu, W.; Prat, A. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts Cell Rep. 2013, 4, 1116-30 10.1016/j.celrep.2013.08.022
-
(2013)
Cell Rep.
, vol.4
, pp. 1116-1130
-
-
Li, S.1
Shen, D.2
Shao, J.3
Crowder, R.4
Liu, W.5
Prat, A.6
-
9
-
-
84888391516
-
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
-
Toy, W.; Shen, Y.; Won, H.; Green, B.; Sakr, R. A.; Will, M. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer Nat. Genet. 2013, 45, 1439-45 10.1038/ng.2822
-
(2013)
Nat. Genet.
, vol.45
, pp. 1439-1445
-
-
Toy, W.1
Shen, Y.2
Won, H.3
Green, B.4
Sakr, R.A.5
Will, M.6
-
10
-
-
1842633460
-
Fulvestrant: pharmacokinetics and pharmacology
-
Robertson, J. F. R.; Harrison, M. Fulvestrant: pharmacokinetics and pharmacology Br. J. Cancer 2004, 90 (Suppl. 1) S7-S10 10.1038/sj.bjc.6601630
-
(2004)
Br. J. Cancer
, vol.90
, pp. S7-S10
-
-
Robertson, J.F.R.1
Harrison, M.2
-
11
-
-
80052736785
-
Fulvestrant revisited: efficacy and safety of the 500-mg dose
-
Howell, A.; Sapunar, F. Fulvestrant revisited: efficacy and safety of the 500-mg dose Clin. Breast Cancer 2011, 11, 204-210 10.1016/j.clbc.2011.02.002
-
(2011)
Clin. Breast Cancer
, vol.11
, pp. 204-210
-
-
Howell, A.1
Sapunar, F.2
-
12
-
-
79958149945
-
The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy
-
Wardell, S. E.; Marks, J. R.; McDonnell, D. P. The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy Biochem. Pharmacol. 2011, 82, 122-130 10.1016/j.bcp.2011.03.031
-
(2011)
Biochem. Pharmacol.
, vol.82
, pp. 122-130
-
-
Wardell, S.E.1
Marks, J.R.2
McDonnell, D.P.3
-
13
-
-
0028263517
-
3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic Acid: A Non-Steroidal Estrogen with Functional Selectivity for Bone over Uterus in Rats
-
Willson, T. M.; Henke; Brad, R.; Momtahen, T. M.; Charifson; Paul, S.; Batchelor; Kenneth, W.; Lubahn; Dennis, B.; Moore; Linda, B.; Oliver; Beverly, B.; Sauls; Howard, R.; Triantafillou, J. A.; Wolfe, S. G.; Baer, P. G. 3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic Acid: A Non-Steroidal Estrogen with Functional Selectivity for Bone over Uterus in Rats J. Med. Chem. 1994, 37, 1550-1552 10.1021/jm00037a002
-
(1994)
J. Med. Chem.
, vol.37
, pp. 1550-1552
-
-
Willson, T.M.1
Henke2
Brad, R.3
Momtahen, T.M.4
Charifson5
Paul, S.6
Batchelor7
Kenneth, W.8
Lubahn9
Dennis, B.10
Moore11
Linda, B.12
Oliver13
Beverly, B.14
Sauls15
Howard, R.16
Triantafillou, J.A.17
Wolfe, S.G.18
Baer, P.G.19
-
14
-
-
0030741983
-
Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone
-
Willson, T. M.; Norris, J. D.; Wagner, B. L.; Asplin, I.; Baer, P.; Brown, H. R.; Jones, S. A.; Henke, B.; Sauls, H.; Wolfe, S.; Morris, D. C.; McDonnell, D. P. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone Endocrinology 1997, 138, 3901-3911 10.1210/endo.138.9.5358
-
(1997)
Endocrinology
, vol.138
, pp. 3901-3911
-
-
Willson, T.M.1
Norris, J.D.2
Wagner, B.L.3
Asplin, I.4
Baer, P.5
Brown, H.R.6
Jones, S.A.7
Henke, B.8
Sauls, H.9
Wolfe, S.10
Morris, D.C.11
Mcdonnell, D.P.12
-
15
-
-
18944381947
-
Structural basis for an unexpected mode of SERM-mediated ER antagonism
-
Wu, Y.-L.; Yang, X.; Ren, Z.; McDonnell, D. P.; Norris, J. D.; Willson, T. M.; Greene, G. L. Structural basis for an unexpected mode of SERM-mediated ER antagonism Mol. Cell 2005, 18, 413-424 10.1016/j.molcel.2005.04.014
-
(2005)
Mol. Cell
, vol.18
, pp. 413-424
-
-
Wu, Y.-L.1
Yang, X.2
Ren, Z.3
McDonnell, D.P.4
Norris, J.D.5
Willson, T.M.6
Greene, G.L.7
-
16
-
-
33746829967
-
Newly discovered orally active pure antiestrogens
-
Kanbe, Y.; Kim, M.-H.; Nishimoto, M.; Ohtake, Y.; Yoneya, T.; Ohizumi, I.; Tsunenari, T.; Taniguchi, K.; Kaiho, S.-I.; Nabuchi, Y.; Araya, H.; Kawata, S.; Morikawa, K.; Jo, J.-C.; Kwon, H.-E.; Limb, H.-S.; Kim, H.-K. Newly discovered orally active pure antiestrogens Bioorg. Med. Chem. Lett. 2006, 16, 4959-4964 10.1016/j.bmcl.2006.06.047
-
(2006)
Bioorg. Med. Chem. Lett.
, vol.16
, pp. 4959-4964
-
-
Kanbe, Y.1
Kim, M.-H.2
Nishimoto, M.3
Ohtake, Y.4
Yoneya, T.5
Ohizumi, I.6
Tsunenari, T.7
Taniguchi, K.8
Kaiho, S.-I.9
Nabuchi, Y.10
Araya, H.11
Kawata, S.12
Morikawa, K.13
Jo, J.-C.14
Kwon, H.-E.15
Limb, H.-S.16
Kim, H.-K.17
-
17
-
-
10744226748
-
Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer
-
Hoffmann, J.; Bohlmann, R.; Heinrich, N.; Hofmeister, H.; Kroll, J.; Kuenzer, H.; Lichtner, R. B.; Nishino, Y.; Parczyk, K.; Sauer, G.; Gieschen, H.; Ulbrich, H.-F.; Martin, R.; Schneider, M. R. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer J. Natl. Cancer Inst. 2004, 96, 210-218 10.1093/jnci/djh022
-
(2004)
J. Natl. Cancer Inst.
, vol.96
, pp. 210-218
-
-
Hoffmann, J.1
Bohlmann, R.2
Heinrich, N.3
Hofmeister, H.4
Kroll, J.5
Kuenzer, H.6
Lichtner, R.B.7
Nishino, Y.8
Parczyk, K.9
Sauer, G.10
Gieschen, H.11
Ulbrich, H.-F.12
Martin, R.13
Schneider, M.R.14
-
18
-
-
20044395599
-
Estrogen receptor ligands. Part 10: Chromanes: old scaffolds for new SERAMs
-
Tan, Q.; Blizzard, T. A.; Morgan, J. D.; Birzin, E. T.; Chan, W.; Yang, Y. T.; Pai, L.-Y.; Hayes, E. C.; DaSilva, C. A.; Warrier, S.; Yudkovitz, J.; Wilkinson, H. A.; Sharma, N.; Fitzgerald, P. M. D.; Li, S.; Colwell, L.; Fisher, J. E.; Adamski, S.; Reszka, A. A.; Kimmel, D.; DiNinno, F.; Rohrer, S. P.; Freedman, L. P.; Schaeffer, J. M.; Hammond, M. L. Estrogen receptor ligands. Part 10: Chromanes: old scaffolds for new SERAMs Bioorg. Med. Chem. Lett. 2005, 15, 1675-1681 10.1016/j.bmcl.2005.01.046
-
(2005)
Bioorg. Med. Chem. Lett.
, vol.15
, pp. 1675-1681
-
-
Tan, Q.1
Blizzard, T.A.2
Morgan, J.D.3
Birzin, E.T.4
Chan, W.5
Yang, Y.T.6
Pai, L.-Y.7
Hayes, E.C.8
DaSilva, C.A.9
Warrier, S.10
Yudkovitz, J.11
Wilkinson, H.A.12
Sharma, N.13
Fitzgerald, P.M.D.14
Li, S.15
Colwell, L.16
Fisher, J.E.17
Adamski, S.18
Reszka, A.A.19
Kimmel, D.20
DiNinno, F.21
Rohrer, S.P.22
Freedman, L.P.23
Schaeffer, J.M.24
Hammond, M.L.25
more..
-
19
-
-
20144376341
-
Discovery of novel quinoline-based estrogen receptor ligands using peptide interaction profiling
-
Hoekstra, W. J.; Patel, H. S.; Liang, X.; Blanc, J-B. E.; Heyer, D. O.; Willson, T. M.; Iannone, M. A.; Kadwell, S. H.; Miller, L. A.; Pearce, K. H.; Simmons, C. A.; Shearin, J. Discovery of novel quinoline-based estrogen receptor ligands using peptide interaction profiling J. Med. Chem. 2005, 48, 2243-2247 10.1021/jm040154f
-
(2005)
J. Med. Chem.
, vol.48
, pp. 2243-2247
-
-
Hoekstra, W.J.1
Patel, H.S.2
Liang, X.3
Blanc, J.-B.E.4
Heyer, D.O.5
Willson, T.M.6
Iannone, M.A.7
Kadwell, S.H.8
Miller, L.A.9
Pearce, K.H.10
Simmons, C.A.11
Shearin, J.12
-
20
-
-
77951033352
-
Thiochroman derivative CH4986399, a new nonsteroidal estrogen receptor down-regulator, is effective in breast cancer models
-
Yoneya, T.; Taniguchi, K.; Nakamura, R.; Tsunenari, T.; Ohizumi, I.; Kanbe, Y.; Morikawa, K.; Kaiho, S.-I.; Yamada-Okabe, H. Thiochroman derivative CH4986399, a new nonsteroidal estrogen receptor down-regulator, is effective in breast cancer models Anticancer Res. 2010, 30, 873-878
-
(2010)
Anticancer Res.
, vol.30
, pp. 873-878
-
-
Yoneya, T.1
Taniguchi, K.2
Nakamura, R.3
Tsunenari, T.4
Ohizumi, I.5
Kanbe, Y.6
Morikawa, K.7
Kaiho, S.-I.8
Yamada-Okabe, H.9
-
21
-
-
78650611572
-
Anti-breast cancer potential of SS5020, a novel benzopyran antiestrogen
-
Suzuki, N.; Liu, X.; Laxmi, Y. R. S.; Okamoto, K.; Kim, H. J.; Zhang, G.; Chen, J. J.; Okamoto, Y.; Shibutani, S. Anti-breast cancer potential of SS5020, a novel benzopyran antiestrogen Int. J. Cancer 2011, 128, 974-982 10.1002/ijc.25659
-
(2011)
Int. J. Cancer
, vol.128
, pp. 974-982
-
-
Suzuki, N.1
Liu, X.2
Laxmi, Y.R.S.3
Okamoto, K.4
Kim, H.J.5
Zhang, G.6
Chen, J.J.7
Okamoto, Y.8
Shibutani, S.9
-
22
-
-
84933059419
-
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts
-
Lai, A.; Kahraman, M.; Govek, S.; Nagasawa, J.; Bonnefous, C.; Julien, J.; Douglas, K.; Sensintaffar, J.; Lu, N.; Lee, K.; Aparicio, A.; Kaufman, J.; Qian, J.; Shao, G.; Prudente, R.; Moon, M. J.; Joseph, J. D.; Darimont, B.; Brigham, D.; Grillot, K.; Heyman, R.; Rix, P. J.; Hager, J. H.; Smith, N. D. Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts J. Med. Chem. 2015, 58, 4888 10.1021/acs.jmedchem.5b00054
-
(2015)
J. Med. Chem.
, vol.58
, pp. 4888
-
-
Lai, A.1
Kahraman, M.2
Govek, S.3
Nagasawa, J.4
Bonnefous, C.5
Julien, J.6
Douglas, K.7
Sensintaffar, J.8
Lu, N.9
Lee, K.10
Aparicio, A.11
Kaufman, J.12
Qian, J.13
Shao, G.14
Prudente, R.15
Moon, M.J.16
Joseph, J.D.17
Darimont, B.18
Brigham, D.19
Grillot, K.20
Heyman, R.21
Rix, P.J.22
Hager, J.H.23
Smith, N.D.24
more..
-
23
-
-
0032581614
-
Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene
-
Rosati, R. L.; Da Silva Jardine, P.; Cameron, K. O.; Thompson, D. D.; Ke, H. Z.; Toler, S. M.; Brown, T. A.; Pan, L. C.; Ebbinghaus, C. F.; Reinhold, A. R.; Elliott, N. C.; Newhouse, B. N.; Tjoa, C. M.; Sweetnam, P. M.; Cole, M. J.; Arriola, M. W.; Gauthier, J. W.; Crawford, D. T.; Nickerson, D. F.; Pirie, C. M.; Qi, H.; Simmons, H. A.; Tkalcevic, G. T. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene J. Med. Chem. 1998, 41, 2928-2931 10.1021/jm980048b
-
(1998)
J. Med. Chem.
, vol.41
, pp. 2928-2931
-
-
Rosati, R.L.1
Da Silva Jardine, P.2
Cameron, K.O.3
Thompson, D.D.4
Ke, H.Z.5
Toler, S.M.6
Brown, T.A.7
Pan, L.C.8
Ebbinghaus, C.F.9
Reinhold, A.R.10
Elliott, N.C.11
Newhouse, B.N.12
Tjoa, C.M.13
Sweetnam, P.M.14
Cole, M.J.15
Arriola, M.W.16
Gauthier, J.W.17
Crawford, D.T.18
Nickerson, D.F.19
Pirie, C.M.20
Qi, H.21
Simmons, H.A.22
Tkalcevic, G.T.23
more..
-
24
-
-
0034989609
-
Understanding the genotoxicity of tamoxifen
-
Phillips, D. H. Understanding the genotoxicity of tamoxifen Carcinogenicity 2001, 22, 839-849 10.1093/carcin/22.6.839
-
(2001)
Carcinogenicity
, vol.22
, pp. 839-849
-
-
Phillips, D.H.1
-
25
-
-
84885524354
-
Selective estrogen receptor modulators
-
Fischer, J. Ganellin, C. R. Rotella, D. P. Wiley-VCH Verlag GmbH: Weinheim, Germany
-
Luniwal, A.; Jetson, R.; Erhardt, P. Selective estrogen receptor modulators. In Analogue-Based Drug Discovery III; Fischer, J.; Ganellin, C. R.; Rotella, D. P., Eds.; Wiley-VCH Verlag GmbH: Weinheim, Germany, 2013; pp 165-185.
-
(2013)
Analogue-Based Drug Discovery III
, pp. 165-185
-
-
Luniwal, A.1
Jetson, R.2
Erhardt, P.3
-
26
-
-
47249138273
-
Selective estrogen receptor modulator chemistry at Merck. A review
-
Blizzard, T. A. Selective estrogen receptor modulator chemistry at Merck. A review Curr. Top. Med. Chem. 2008, 8, 792-812 10.2174/156802608784535066
-
(2008)
Curr. Top. Med. Chem.
, vol.8
, pp. 792-812
-
-
Blizzard, T.A.1
-
27
-
-
79251504654
-
Lasofoxifene, from the preclinical drug discovery to the treatment of postmenopausal osteoporosis
-
Gennari, L.; Merlotti, D.; Stolakis, K.; Nuti, R. Lasofoxifene, from the preclinical drug discovery to the treatment of postmenopausal osteoporosis Expert Opin. Drug Discovery 2011, 6 (2) 205-217 10.1517/17460441.2011.547188
-
(2011)
Expert Opin. Drug Discovery
, vol.6
, Issue.2
, pp. 205-217
-
-
Gennari, L.1
Merlotti, D.2
Stolakis, K.3
Nuti, R.4
-
28
-
-
4243241249
-
The Pictet-Spengler condensation: a new direction for an old reaction
-
Cox, E. D.; Cook, J. M. The Pictet-Spengler condensation: a new direction for an old reaction Chem. Rev. 1995, 95, 1797-842 10.1021/cr00038a004
-
(1995)
Chem. Rev.
, vol.95
, pp. 1797-1842
-
-
Cox, E.D.1
Cook, J.M.2
-
29
-
-
77954068671
-
The asymmetric Pictet-Spengler reaction
-
Lorenz, M.; Van Linn, M. L.; Cook, J. M. The asymmetric Pictet-Spengler reaction Curr. Org. Synth. 2010, 7, 189-223 10.2174/157017910791163011
-
(2010)
Curr. Org. Synth.
, vol.7
, pp. 189-223
-
-
Lorenz, M.1
Van Linn, M.L.2
Cook, J.M.3
-
30
-
-
80052483777
-
The Pictet-Spengler Reaction in Nature and in Organic Chemistry
-
Stockigt, J.; Antonchick, A. P.; Wu, F.-R.; Waldmann, H. The Pictet-Spengler Reaction in Nature and in Organic Chemistry Angew. Chem., Int. Ed. 2011, 50, 8538-8564 10.1002/anie.201008071
-
(2011)
Angew. Chem., Int. Ed.
, vol.50
, pp. 8538-8564
-
-
Stockigt, J.1
Antonchick, A.P.2
Wu, F.-R.3
Waldmann, H.4
-
31
-
-
33646874831
-
A simple method for the synthesis of 1-substituted β-carboline derivatives from tryptamine and carboxylic acids in polyphosphoric acid
-
Ivanov, I.; Nikolova, S.; Statkova-Abeghe, S. A simple method for the synthesis of 1-substituted β-carboline derivatives from tryptamine and carboxylic acids in polyphosphoric acid Heterocycles 2005, 65, 2483-2492 10.3987/COM-05-10484
-
(2005)
Heterocycles
, vol.65
, pp. 2483-2492
-
-
Ivanov, I.1
Nikolova, S.2
Statkova-Abeghe, S.3
-
32
-
-
84931301519
-
A screening Assay Cascade to Identify and Characterize Novel Selective Estrogen Receptor Downregulators (SERDs)
-
Callis, R.; Rabow, A.; Tonge, M.; Bradbury, R.; Challinor, M.; Roberts, K.; Jones, K.; Walker, G. A screening Assay Cascade to Identify and Characterize Novel Selective Estrogen Receptor Downregulators (SERDs) J. Biomol. Screening 2015, 20, 748 10.1177/1087057115580298
-
(2015)
J. Biomol. Screening
, vol.20
, pp. 748
-
-
Callis, R.1
Rabow, A.2
Tonge, M.3
Bradbury, R.4
Challinor, M.5
Roberts, K.6
Jones, K.7
Walker, G.8
-
33
-
-
84928485170
-
Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators
-
Degorce, S.; Bailey, A.; Callis, R.; De Savi, C.; Ducray, R.; Lamont, G.; MacFaul, P.; Maudet, M.; Martin, S.; Morgentin, R.; Norman, R. A.; Peru, A.; Pink, J. H.; Ple, P. A.; Roberts, B.; Scott, J. S. Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators J. Med. Chem. 2015, 58, 3522-3533 10.1021/acs.jmedchem.5b00066
-
(2015)
J. Med. Chem.
, vol.58
, pp. 3522-3533
-
-
Degorce, S.1
Bailey, A.2
Callis, R.3
De Savi, C.4
Ducray, R.5
Lamont, G.6
MacFaul, P.7
Maudet, M.8
Martin, S.9
Morgentin, R.10
Norman, R.A.11
Peru, A.12
Pink, J.H.13
Ple, P.A.14
Roberts, B.15
Scott, J.S.16
-
34
-
-
19644397122
-
-
Eds. Methods and Principles in Medicinal Chemistry, Wiley-VCH Verlag GmbH: Weinheim, Germany
-
van de Waterbeemd, H.; Lennernas, H.; Artursson, P.; Mannhold, R.; Kubinyi, H.; Folkers, G., Eds. Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability; Methods and Principles in Medicinal Chemistry, Vol. 18; Wiley-VCH Verlag GmbH: Weinheim, Germany, 2003; pp 3-242.
-
(2003)
Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability
, vol.18
, pp. 3-242
-
-
Van De Waterbeemd, H.1
Lennernas, H.2
Artursson, P.3
Mannhold, R.4
Kubinyi, H.5
Folkers, G.6
-
35
-
-
0141992796
-
The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1′,2′:1,6]pyrido[3,4-b]indole-1,4-dione analogues
-
Daugan, A.; Grondin, P.; Ruault, C.; Le Monnier de Gouville, A.-C.; Coste, H.; Linget, J. M.; Kirilovsky, J.; Hyafil, F.; Labaudiniere, R. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1′,2′:1,6]pyrido[3,4-b]indole-1,4-dione analogues J. Med. Chem. 2003, 46, 4533-4542 10.1021/jm0300577
-
(2003)
J. Med. Chem.
, vol.46
, pp. 4533-4542
-
-
Daugan, A.1
Grondin, P.2
Ruault, C.3
Le Monnier De Gouville, A.-C.4
Coste, H.5
Linget, J.M.6
Kirilovsky, J.7
Hyafil, F.8
Labaudiniere, R.9
-
36
-
-
77954745330
-
Spirotetrahydro β-Carbolines (Spiroindolones): A New Class of Potent and Orally Efficacious Compounds for the Treatment of Malaria
-
Yeung, B. K. S.; Zou, B.; Rottmann, M.; Lakshminarayana, S. B.; Ang, S. H.; Leong, S. Y.; Tan, J.; Wong, J.; Keller-Maerki, S.; Fischli, C.; Goh, A.; Schmitt, E. K.; Krastel, P.; Francotte, E.; Kuhen, K.; Plouffe, D.; Henson, K.; Wagner, T.; Winzeler, E. A.; Petersen, F.; Brun, R.; Dartois, V.; Diagana, T. T.; Keller, T. H.; Spirotetrahydro β-Carbolines (Spiroindolones): A New Class of Potent and Orally Efficacious Compounds for the Treatment of Malaria J. Med. Chem. 2010, 53, 5155-5164 10.1021/jm100410f
-
(2010)
J. Med. Chem.
, vol.53
, pp. 5155-5164
-
-
Yeung, B.K.S.1
Zou, B.2
Rottmann, M.3
Lakshminarayana, S.B.4
Ang, S.H.5
Leong, S.Y.6
Tan, J.7
Wong, J.8
Keller-Maerki, S.9
Fischli, C.10
Goh, A.11
Schmitt, E.K.12
Krastel, P.13
Francotte, E.14
Kuhen, K.15
Plouffe, D.16
Henson, K.17
Wagner, T.18
Winzeler, E.A.19
Petersen, F.20
Brun, R.21
Dartois, V.22
Diagana, T.T.23
Keller, T.H.24
more..
-
37
-
-
84945392145
-
-
http://www.clinicaltrials.gov/ct2/results?term=PTC299.
-
-
-
-
38
-
-
84945359331
-
-
PCT Int. Appl.
-
Hwang, P. S.; Moon, Y.-C.; Arasu, T.; Qi, H.; Almstead, N. Process for the preparation chiral tetrahydro-β-carbolines via resolution. PCT Int. Appl. WO 2010138644, 2010.
-
(2010)
Process for the preparation chiral tetrahydro-β-carbolines via resolution
-
-
Hwang, P.S.1
Moon, Y.-C.2
Arasu, T.3
Qi, H.4
Almstead, N.5
-
39
-
-
84945410643
-
-
PCT Int. Appl.
-
Almstead, N.; Arasu, T.; Choi, S.; Cao, L.; Campbell, J.; Corson, D.; Davis, T. W.; Graci, J. D.; Gu, Z.; Hwang, P. S.; Lennox, W.; Miao, H. H.; Miller, L.; Moon, Y.-C.; Qi, H.; Trotta, C.; Weetall, M. L. Preparation of phenyltetrahydropyridoindole derivatives for use in treating cancer and non-neoplastic conditions. PCT Int. Appl. WO 2010138758, 2010.
-
(2010)
Preparation of phenyltetrahydropyridoindole derivatives for use in treating cancer and non-neoplastic conditions
-
-
Almstead, N.1
Arasu, T.2
Choi, S.3
Cao, L.4
Campbell, J.5
Corson, D.6
Davis, T.W.7
Graci, J.D.8
Gu, Z.9
Hwang, P.S.10
Lennox, W.11
Miao, H.H.12
Miller, L.13
Moon, Y.-C.14
Qi, H.15
Trotta, C.16
Weetall, M.L.17
-
40
-
-
36749018204
-
Privileged structures: a useful concept for the rational design of new lead drug candidates
-
Duarte, C. D.; Barreiro, E. J.; Fraga, C. A. M. Privileged structures: a useful concept for the rational design of new lead drug candidates Mini-Rev. Med. Chem. 2007, 7, 1108-1119 10.2174/138955707782331722
-
(2007)
Mini-Rev. Med. Chem.
, vol.7
, pp. 1108-1119
-
-
Duarte, C.D.1
Barreiro, E.J.2
Fraga, C.A.M.3
-
41
-
-
84880147352
-
Privileged structures as leads in medicinal chemistry
-
Costantino, L.; Barlocco, D. Privileged structures as leads in medicinal chemistry Front. Med. Chem. 2010, 5, 381-422
-
(2010)
Front. Med. Chem.
, vol.5
, pp. 381-422
-
-
Costantino, L.1
Barlocco, D.2
-
42
-
-
35148869577
-
Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators
-
Wittmann, B. M.; Sherk, A.; McDonnell, D. P. Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators Cancer Res. 2007, 67, 9549-9560 10.1158/0008-5472.CAN-07-1590
-
(2007)
Cancer Res.
, vol.67
, pp. 9549-9560
-
-
Wittmann, B.M.1
Sherk, A.2
McDonnell, D.P.3
-
43
-
-
78149501152
-
The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer
-
McDonnell, D. P.; Wardell, S. E. The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer Curr. Opin. Pharmacol. 2010, 10, 620-628 10.1016/j.coph.2010.09.007
-
(2010)
Curr. Opin. Pharmacol.
, vol.10
, pp. 620-628
-
-
McDonnell, D.P.1
Wardell, S.E.2
-
44
-
-
0023701360
-
Novel antioestrogens without partial agonist activity
-
Wakeling, A. E.; Bowler, J. Novel antioestrogens without partial agonist activity J. Steroid Biochem. 1988, 31, 645-653 10.1016/0022-4731(88)90014-3
-
(1988)
J. Steroid Biochem.
, vol.31
, pp. 645-653
-
-
Wakeling, A.E.1
Bowler, J.2
-
45
-
-
0026395885
-
A Potent Specific Pure Antiestrogen with Clinical Potential
-
Wakeling, A. E.; Dukes, M.; Bowler, J. A Potent Specific Pure Antiestrogen with Clinical Potential Cancer Res. 1991, 51, 3867-3873
-
(1991)
Cancer Res.
, vol.51
, pp. 3867-3873
-
-
Wakeling, A.E.1
Dukes, M.2
Bowler, J.3
-
46
-
-
80052262709
-
PHRMA CPCDC initiative on predictive models of human pharmacokinetics, Part 5: Prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach
-
Poulin, P.; Jones, R. D. O.; Jones, H. M.; Gibson, C. R.; Rowland, M.; Chien, J. Y.; Ring, B. J.; Adkison, K. K.; Ku, M. S.; He, H.; Vuppugalla, R.; Marathe, P.; Fischer, V.; Dutta, S.; Sinha, V. K.; Bjoernsson, T.; Lave, T.; Yates, J. W. T. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, Part 5: Prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach J. Pharm. Sci. 2011, 100, 4127-4157 10.1002/jps.22550
-
(2011)
J. Pharm. Sci.
, vol.100
, pp. 4127-4157
-
-
Poulin, P.1
Jones, R.D.O.2
Jones, H.M.3
Gibson, C.R.4
Rowland, M.5
Chien, J.Y.6
Ring, B.J.7
Adkison, K.K.8
Ku, M.S.9
He, H.10
Vuppugalla, R.11
Marathe, P.12
Fischer, V.13
Dutta, S.14
Sinha, V.K.15
Bjoernsson, T.16
Lave, T.17
Yates, J.W.T.18
-
47
-
-
38149070200
-
Fluorine in medicinal chemistry
-
Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. Fluorine in medicinal chemistry Chem. Soc. Rev. 2008, 37, 320-330 10.1039/B610213C
-
(2008)
Chem. Soc. Rev.
, vol.37
, pp. 320-330
-
-
Purser, S.1
Moore, P.R.2
Swallow, S.3
Gouverneur, V.4
-
48
-
-
84945431966
-
A Novel Oral Selective Estrogen Receptor Down-regulator, AZD9496, drives Tumour Growth Inhibition in Estrogen Receptor positive and ESR1 Mutant Models
-
manuscript submitted
-
Weir, H. M.; Bradbury, R. H.; Lawson, M.; de Almeida, C.; Andrews, D. M.; Buttar, D.; Callis, R. J.; Curwen, J. O.; Hulse, M.; Donald, C. S.; Gingell, H.; Hussain, S.; Karoutchi, G.; Lamont, S. G.; MacFaul, P.; Moss, T.; Norman, R. A.; Pearson, S. E.; Rabow, A. A.; Tonge, M.; Walker, G. E.; Wilson, Z.; Powell, S.; Campbell, H.; Ghazoui, Z.; Davies, G.; Rowlinson, R.; Sadler, C.; Richmond, G.; Mazzola, A. M.; D'Cruz, C.; De Savi, C. A Novel Oral Selective Estrogen Receptor Down-regulator, AZD9496, drives Tumour Growth Inhibition in Estrogen Receptor positive and ESR1 Mutant Models. Cancer Res. 2015, manuscript submitted.
-
(2015)
Cancer Res.
-
-
Weir, H.M.1
Bradbury, R.H.2
Lawson, M.3
De Almeida, C.4
Andrews, D.M.5
Buttar, D.6
Callis, R.J.7
Curwen, J.O.8
Hulse, M.9
Donald, C.S.10
Gingell, H.11
Hussain, S.12
Karoutchi, G.13
Lamont, S.G.14
MacFaul, P.15
Moss, T.16
Norman, R.A.17
Pearson, S.E.18
Rabow, A.A.19
Tonge, M.20
Walker, G.E.21
Wilson, Z.22
Powell, S.23
Campbell, H.24
Ghazoui, Z.25
Davies, G.26
Rowlinson, R.27
Sadler, C.28
Richmond, G.29
Mazzola, A.M.30
D'Cruz, C.31
De Savi, C.32
more..
-
49
-
-
34447337731
-
Prediction of human pharmacokinetics - gastrointestinal absorption
-
Fagerholm, U. Prediction of human pharmacokinetics-gastrointestinal absorption J. Pharm. Pharmacol. 2007, 59, 905-916 10.1211/jpp.59.7.0001
-
(2007)
J. Pharm. Pharmacol.
, vol.59
, pp. 905-916
-
-
Fagerholm, U.1
-
50
-
-
79953311521
-
A A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance
-
Miller, T. W.; Balko, J. M.; Ghazoui, Z.; Dunbier, A.; Anderson, H.; Dowsett, M. A A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance Clin. Cancer Res. 2011, 17, 2024-2034 10.1158/1078-0432.CCR-10-2567
-
(2011)
Clin. Cancer Res.
, vol.17
, pp. 2024-2034
-
-
Miller, T.W.1
Balko, J.M.2
Ghazoui, Z.3
Dunbier, A.4
Anderson, H.5
Dowsett, M.6
|